| Description : |
PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. It is a 50 kDa glycoprotein produced and secreted in many tissues throughout the body. A major component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. In addition, PEDF is able to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The neuroprotective effects of PEDF are achieved through suppression of neuronal apoptosis induced by peroxide, glutamate, or other neurotoxins. The recent identification of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. To date, PEDF-R is the only signaling receptor known to be used by a serpin family member. The unique range of PEDF activities implicate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF also has the potential to be useful in the treatment of various angiogenesis-related diseases including a number of cancers. |
| Source : |
E. coli |
| Species : |
Human |
| Form : |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Bio-activity : |
Data Not Available. |
| Molecular Mass : |
Approximately 44.5 KDa, a single non-glycosylated polypeptide chain containing 400 amino acids. |
| Protein Length : |
400 |
| AA Sequence : |
MQNPASPPEEGSPDPDSTGALVEEE DPFFKVPVNKLAAAVSNFGYDLYRV RSSMSPTTNVLLSPLSVATALSALS LGAEQRTESIIHRALYYDLISSPDI HGTYKELLDTVTAPQKNLKSASRIV FEKKLRIKSSFVAPLEKSYGTRPRV LTGNPRLDLQEINNWVQAQMKGKLA RSTKEIPDEISILLLGVAHFKGQWV TKFDSRKTSLEDFYLDEERTVRVPM MSDPKAVLRYGLDSDLSCKIAQLPL TGSMSIIFFLPLKVTQNLTLIEESL TSEFIHDIDRELKTVQAVLTVPKLK LSYEGEVTKSLQEMKLQSLFDSPDF SKITGKPIKLTQVEHRAGFEWNEDG AGTTPSPGLQPAHLTFPLDYHLNQP FIFVLRDTDTGALLFIGKILDPRGP |
| Endotoxin : |
Less than 1 EU/mg of rHuPEDF as determined by LAL method. |
| Purity : |
>95% by SDS-PAGE and HPLC analyses. |
| Storage : |
This lyophilized preparation is stable at 2-8 centigrade, but should be kept at -20 centigrade for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 centigrade. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 to -70 centigrade. Avoid repeated freeze/thaw cycles. |
| Storage Buffer : |
Lyophilized from a 0.2mm filtered concentrated solution in 20mM PB, pH7.4, 150mM NaCl. |
| Reconstitution : |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 centigrade. Further dilutions should be made in appropriate buffered solutions. |
